Merck will be interested in partnering, data was very good. the vaccine will be paired with Keytruda in a patented combo. Merck agreed to $600m in milestone payments for an untested vax. with these excellent p2 results, a deal for this vax could be worth $1 billion or more, with more up front cash. real investors will figure this out soon and the stock will rise next week.
Market Data 
Markets 
AI
